We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Discovery of Distinctive Genetic Signatures Accelerates Biomarker Discovery

By LabMedica International staff writers
Posted on 27 May 2009
A system has been developed to speed the biomarker discovery process for the development of rapid diagnostic tests.

With the new system scientists rapidly discovered a DNA barcode for H1N1 Flu using genomic sequences of the virus isolated from infected patients and provided by the U.S. National Institute of Health (NIH; Bethesda, MD, USA).

Siemens Corporate Research Inc. (SCR; Princeton, NJ, USA) developed the RAPID2 system, which combines information technology with improved genomic sequencing, to quickly identify unique genomic signatures for pathogens. The new system is suitable for discovering genetic targets for cancer diagnostics as well as for disease outbreaks, healthcare-associated infections, and for use within the food and water industries.

Signatures are the foundation for a new generation of molecular diagnostic tests for the rapid detection of healthcare-associated infections such as the potentially dangerous Methicillin-Resistant Staphylococcus aureus (MRSA).

Gayle Wittenberg, program manager at SCR and colleagues utilized complex information technology models to focus on genetic targets that quickly identify pathogenic bacteria. "The advantage of our RAPID2 system is that it provides an efficient framework for quickly identifying new biomarkers based on the genomic sequence of a particular pathogen," said Dr. Wittenberg. "In the event of a pandemic, such as the recent H1N1 Flu outbreak, our system would enable a rapid response with the development of a strain-specific diagnostic test. This would help medical professionals manage an outbreak more effectively from the outset."

SCR in New Jersey is one of several Siemens Corporate Technology research and development centers worldwide. The company transforms research into practical solutions and services.

Related Links:

U.S. National Institute of Health
Siemens Corporate Research Inc.




New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Automatic Hematology Analyzer
DH-800 Series

Latest Molecular Diagnostics News

Blood Test Detects Ovarian Cancer with High Accuracy
27 May 2009  |   Molecular Diagnostics

Genetic Testing of IVF-Created Embryos Speeds Up Conception in Women Over 35
27 May 2009  |   Molecular Diagnostics

Cord Blood Test Predicts Newborn’s Risk of Developing Type 2 Diabetes
27 May 2009  |   Molecular Diagnostics